fashion -WSS

fashion

author：hotspot 2025-10-02 07:45:05 - browse：3

Illumina, the largest maker of DNA-sequencing technology and a storied name in the biotechnology industry, named Jacob Thaysen, a 10-year-veteran at life sciences-tools firm Agilent, as its new CEO.

The appointment follows a bitter board fight that ended with the departure of Francis deSouza, who had been Illumina’s CEO since 2016. The battle, tipped off by Illumina’s troubled acquisition of cancer diagnostics firm Grail, had involved a proxy fight staged by activist investor Carl Icahn.

During the battle, there had been speculation that Jay Flatley, deSouza’s predecessor, could return. Under Flatley, Illumina had grown from an upstart to the dominant player in a field that has proved pivotal for medical research and delivered sizable returns to investors.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Why we need mandatory labeling of GMO products

focus

WSS

Why we need mandatory labeling of GMO products

Humana sues Biden admin over Medicare Advantage audit rule

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Listen: Biogen's potential pivot, & Illumina's next chapter

A rare thyroid diagnosis led to unexpected, all

Illumina names Agilent executive as new CEO

knowledge

fashion

focus

Medical records are filled with copy

Unmasking the 'centricity' illusion in clinical trials

BioMarin wins approval for gene therapy to treat hemophilia A

Stem cell treatment guidelines are released by FDA

Cancer drug shortages should be causing more outrage

Should insurance cover cosmetic surgery?

BioMarin wins approval for gene therapy to treat hemophilia A

Advances in CAR

Psychedelics group wrestles with new pharma identity

Why some fertility treatments produce more boy babies

explore

What drug price negotiations mean for Medicare Part D

Hospitals need to get ahead of regulations on climate change

The (many) problems with a new study criticizing cancer screening

Snackable artificial intelligence, expert AI, and the pharma industry

J&J reports mixed data on next

Advances in CAR

focus

focus

hotspot

leisure time